Combined Oral Contraceptive Use May Triple the Risk of Cryptogenic Stroke in Young Women
ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.
Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype
Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.
Colonoscopy Completion Up 69% With Patient Navigation Program After FIT: Daily Dose
Your daily dose of the clinical news you may have missed.
The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care
At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.
Roflumilast Topical Foam 0.3% Approved to Treat Plaque Psoriasis in People Aged 12 Years and Older
Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.
Novel CBD Cream Shows Promise in Protecting Skin from UV-A Damage in First-Ever In-Human Trial
Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.
Moderna Announces Withdrawal of BLA for Flu/COVID-19 Combination Vaccine
Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.
Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: Phase 3b WAYFINDER Trial
The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.
Atopic Dermatitis Burden in Older Adults May Surge by 2050: Daily Dose
From Screening to Support: How PCPs Can Tackle PPD
ACOG 2025: Joy Baker, MD, urged primary care clinicians to screen early, refer confidently, and help change the statistics on maternal mental health.
Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease
Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.
Johanna Finkle, MD, on Approaching Weight Loss Discussions with Reproductive-Aged Patients
ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.
Primary Care Clinicians Diagnose Nearly Half of Youth MDD, Report Reveals, Often During a Crisis
Youth depression is often diagnosed during crisis events, underscoring the need for primary care education and enhanced collaborative care resources.
FDA Narrows COVID-19 Vaccine Access to High-Risk Groups, Demands New Trials for Healthy Adults
The FDA's new approach to evaluating and approving COVID-19 vaccines will move the US away from a one-size-fits-all approach and closer to policy in other countries.
Elinzanetant Effective for VMS Across BMI, Smoking Status: Daily Dose
PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD
ACOG 2025: Elizabeth Mollard, PhD, discusses her research on how Medicaid policies influence postpartum depression screening rates.
Single Dose of Arexvy RSV Vaccine Shows 3-Year Protection in Older Adults: Daily Dose
Real-World Memory Clinic Data Suggest Lecanemab Use Is Feasible, Practical for Adults with Alzheimer Disease
Adults with early AD who were treated with lecanemab in a specialty memory clinic experienced adverse events comparable to those seen in clinical trials.
“I’m Just Tired”: Listening for the Words Patients Actually Use
ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.
Investigational Oral Medication for OSA Meets Primary Endpoints in Phase 3 Clinical Trial
The anti-apneic neuromuscular modulator AD109 targets the root cause of OSA by increasing upper airway muscle tone during sleep, according to Apnimed.
